Amarin names new CEO

MYSTIC, Conn. A company that develops drugs for cardiovascular disease has appointed a new leader.

Amarin announced Tuesday the appointment of Colin Stewart as president, CEO and as a board member.

The company currently is conducting a late-stage clinical trial of AMR101, a treatment for high triglycerides.

Login or Register to post a comment.